Teva Pharmaceutical Industries vs Vertex Pharmaceuticals
TEVA and VRTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TEVA and VRTX compare
Vertex Pharmaceuticals is the larger company, worth 2.8 times as much as Teva Pharmaceutical Industries ($139B against $49.4B).
On earnings, Vertex Pharmaceuticals is cheaper: it trades at 31.8× trailing earnings, against 70.7× for Teva Pharmaceutical Industries.
Vertex Pharmaceuticals grew revenue faster over the last twelve months (10.2% versus −15.2% for Teva Pharmaceutical Industries).
Vertex Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.0% compared with 5.0% at Teva Pharmaceutical Industries.
Vertex Pharmaceuticals scores higher on the StockData Score (15 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TEVA | VRTX |
|---|---|---|
| Size and price | ||
| Market cap | $49.4B | $139B |
| Share price | $42.40 | $547.03 |
| Change, 1 year | 76.9% | 29.9% |
| Change, 5 years | 377% | 199% |
| Beta (5Y) | 0.98 | 0.53 |
| Employees | 34K | 600K |
| StockData Score | ||
| Total score | 7 | 15 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 | 6 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 70.7× | 31.8× (better) |
| P/S | 3.5× (better) | 11.0× |
| P/B | 6.4× (better) | 6.8× |
| EV/EBITDA | 19.4× (better) | 26.2× |
| P/FCF | 36.7× | 36.5× (better) |
| PEG | – | 5.20 |
| FCF yield | 2.7% | 2.7% (better) |
| Fair value | $19.87 | $425.95 |
| Margin of safety | −113% | −28.4% (better) |
| Growth | ||
| Revenue growth (TTM) | −15.2% | 10.2% (better) |
| Revenue growth, 5Y average | 0.71% | 14.1% (better) |
| Net income growth (TTM) | – | 21.1% |
| EPS growth (TTM) | – | 22.4% |
| EPS growth, 5Y average | – | 8.3% |
| Profitability | ||
| Gross margin | 64.4% | 86.0% (better) |
| Operating margin | 11.4% | 38.0% (better) |
| Net margin | 5.0% | 35.0% (better) |
| FCF margin | 9.6% | 30.2% (better) |
| Return on equity | 9.7% | 23.5% (better) |
| Return on invested capital | 23.0% | 34.4% (better) |
| Financial health | ||
| Debt / equity | 0.58 (better) | 0.00 |
| Net debt / EBITDA | 0.33 | – |
| Current ratio | 0.88 | 3.19 (better) |
| Altman Z-score | 0.86 | 13.81 (better) |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | – | 1.4% |
| Shareholder yield | 0.00% | 1.4% (better) |
| Ownership | ||
| Held by institutions | – | 95.6% |
| Held by insiders | 0.43% | 0.22% |
| Insider net buying, 12 months | −$108M (better) | −$131M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.4% | 1.9% |
Go deeper
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
- VRTX stock overview
- VRTX income statement
- VRTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.